351 Vor Bbiopharma 2022.10.05 Genevieve De Manio Photography Scaled Aspect Ratio 1200 384

Platform & Pipeline

We are developing a proprietary platform

There is potential to enable treatment-resistant Hematopoietic Stem Cell Transplants (HSCTs) that allow new, potentially curative targeted therapy opportunities for AML and other blood cancers.

Our Platform

Vor Bio is developing a new treatment platform based upon proven technologies in genome engineering, engineered Hematopoietic Stem Cell (eHSC) biology, and CAR-T cells that could change the standard of care for blood cancers.

Our Pipeline

Our pipeline demonstrates the strength and potential of our novel platform, with our lead clinical-stage program currently recruiting patients with relapsed/refractory AML.

Our Approach

We aim to protect the healthy cells, expose the cancer, and change the standard of care for HSCTs.